MX348592B - Sustitutos de proteinas modificadas post-traduccionalmente y usos de los mismos. - Google Patents

Sustitutos de proteinas modificadas post-traduccionalmente y usos de los mismos.

Info

Publication number
MX348592B
MX348592B MX2013009262A MX2013009262A MX348592B MX 348592 B MX348592 B MX 348592B MX 2013009262 A MX2013009262 A MX 2013009262A MX 2013009262 A MX2013009262 A MX 2013009262A MX 348592 B MX348592 B MX 348592B
Authority
MX
Mexico
Prior art keywords
post
translationally modified
substitute
modified proteins
substitutes
Prior art date
Application number
MX2013009262A
Other languages
English (en)
Other versions
MX2013009262A (es
Inventor
A Halperin Jose
Chorev Michael
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2013009262A publication Critical patent/MX2013009262A/es
Publication of MX348592B publication Critical patent/MX348592B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos que son sustitutos de proteínas modificadas post-traduccionalmente y usos de las mismas. Los compuestos sustitutos de la invención típicamente comprenden epítopes antigénicos (uno de los cuales lleva una modificación post-traduccional) que están unidos por enlace éter por un enlazador flexible e hidrófilo. El compuesto resultante se comporta como un sustituto de la proteína modificada post- traduccionalmente debido a que conserva el carácter de los antígenos incluidos y permite reconocimiento por anticuerpos específicos que apuntan a los antígenos individuales. En un aspecto, los compuestos sustitutos de la invención comprenden un epítope terminal C y un epítope glucosado de CD59 humana. Los métodos de la invención permiten cuantificación de los niveles de CD59 glucosada en el suero en sujetos humanos, particularmente aquellos con diabetes o pre-diabetes. Esta plataforma tecnológica de sustitutos de proteína modificada post-traduccionalmente puede aplicarse a otras enfermedades asociadas con proteínas modificadas post-traduccionalmente (v.gr., enfermedades auto-inmunes tales como esclerosis múltiple, artritis reumatoide, y lupus eriteimatoso sistémico).
MX2013009262A 2011-02-10 2012-02-10 Sustitutos de proteinas modificadas post-traduccionalmente y usos de los mismos. MX348592B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441575P 2011-02-10 2011-02-10
PCT/US2012/024645 WO2012109538A2 (en) 2011-02-10 2012-02-10 Surrogates of post-translationally modified proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2013009262A MX2013009262A (es) 2014-01-17
MX348592B true MX348592B (es) 2017-06-12

Family

ID=46639217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009343A MX377572B (es) 2011-02-10 2012-02-10 Sustitutos de proteínas modificadas post-traduccionalmente y usos de los mismos.
MX2013009262A MX348592B (es) 2011-02-10 2012-02-10 Sustitutos de proteinas modificadas post-traduccionalmente y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009343A MX377572B (es) 2011-02-10 2012-02-10 Sustitutos de proteínas modificadas post-traduccionalmente y usos de los mismos.

Country Status (7)

Country Link
US (2) US9417248B2 (es)
EP (1) EP2673293B1 (es)
AU (3) AU2012214259B2 (es)
BR (1) BR112013020274A2 (es)
CA (1) CA2826020C (es)
MX (2) MX377572B (es)
WO (1) WO2012109538A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068006B2 (en) 2010-08-25 2015-06-30 President And Fellows Of Harvard College Glycated CD59 peptides, their preparation, and uses thereof
CA2826020C (en) * 2011-02-10 2020-12-01 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
WO2015084994A1 (en) * 2013-12-03 2015-06-11 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
PL411390A1 (pl) 2015-02-26 2016-08-29 Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akademii Nauk Sposób wczesnego wykrywania stanu przedcukrzycowego lub cukrzycy, zwłaszcza typu 2, oraz jej powikłań, w szczególności kardiomiopatii cukrzycowej
CA3018129A1 (en) * 2016-03-18 2017-09-21 Department Of Biotechnology Multi-functional chemical agents, and the method for protein modification
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
IT201700105213A1 (it) * 2017-09-20 2019-03-20 Fluidia S R L Metodo per la valutazione quantitativa in biologico, di proteine native e modificate e suo uso
WO2022241236A2 (en) * 2021-05-13 2022-11-17 Mellitus, Llc Methods and reagents for protein analysis
WO2025064657A1 (en) * 2023-09-19 2025-03-27 The Johns Hopkins University Mass spectrometry-cleavable photo-crosslinkers for proteome-wide photo-crosslinking mass spectrometry

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536418A (en) * 1895-03-26 Michael clooney
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US6835545B2 (en) * 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
WO2004045520A2 (en) * 2002-11-15 2004-06-03 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
AU2004209401A1 (en) 2003-01-30 2004-08-19 Applied Biosystems, Llc. Methods, mixtures, kits and compositions pertaining to analyte determination
GB2409456B (en) 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
WO2007123708A2 (en) * 2006-03-31 2007-11-01 Epitome Biosystems, Inc. Post translational modification pattern analysis
WO2007133623A2 (en) * 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
US9068006B2 (en) * 2010-08-25 2015-06-30 President And Fellows Of Harvard College Glycated CD59 peptides, their preparation, and uses thereof
CA2826020C (en) * 2011-02-10 2020-12-01 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
WO2015084994A1 (en) * 2013-12-03 2015-06-11 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes

Also Published As

Publication number Publication date
BR112013020274A2 (pt) 2016-11-22
US20140024056A1 (en) 2014-01-23
US20170199201A2 (en) 2017-07-13
EP2673293A2 (en) 2013-12-18
EP2673293A4 (en) 2014-12-31
CA2826020C (en) 2020-12-01
AU2012214259A2 (en) 2014-04-03
AU2012214259A1 (en) 2013-09-12
MX377572B (es) 2025-03-10
AU2012214259B2 (en) 2017-02-23
WO2012109538A8 (en) 2012-10-04
US9417248B2 (en) 2016-08-16
AU2018250392A1 (en) 2018-11-08
EP2673293B1 (en) 2020-09-16
WO2012109538A3 (en) 2012-11-22
WO2012109538A2 (en) 2012-08-16
CA2826020A1 (en) 2012-08-16
US10309973B2 (en) 2019-06-04
US20170023589A1 (en) 2017-01-26
MX2013009262A (es) 2014-01-17
AU2017203280B2 (en) 2018-07-19
AU2017203280A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX348592B (es) Sustitutos de proteinas modificadas post-traduccionalmente y usos de los mismos.
MX2016003961A (es) Composiciones de fragmentos de proteinas de seda y articulos fabricados a partir de las mismas.
AR121002A2 (es) Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica
MX2020011744A (es) Molecula de polipeptido con especificidad dual mejorada.
CL2017002761A1 (es) Proteínas de fusión
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
PE20190976A1 (es) Anticuerpos de union a cd3
CL2019003000A1 (es) Proteínas de unión a antígenos trem2 y usos de estas.
CL2018000461A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
MX387324B (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX2019008221A (es) Anticuerpo anti-gpc3.
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
MX385679B (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
EP3546481A3 (en) Anti-interleukin 22 (il-22) antibody and uses thereof
EP2581113A4 (en) ANTI-TIM-3 ANTIBODY
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20171336A1 (es) Anticuerpos contra tau y sus usos
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada

Legal Events

Date Code Title Description
FG Grant or registration